MDGL β€” MADRIGAL PHARMACEUTICALS INC

Ownership history in EcoR1 Capital, LLC  Β·  9 quarters on record

This page tracks every 13F SEC filing in which EcoR1 Capital, LLC reported a position in MADRIGAL PHARMACEUTICALS INC (MDGL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
5.31% (2018 Q2)
πŸ“Š Avg. % of fund
1.41%
πŸ“… First filed
2017 Q4
πŸ“… Last filed
2025 Q3
⏱ Quarters held
9

Position Intelligence

EcoR1 Capital, LLC Γ— MDGL AI Analytics

πŸ“‰ EcoR1 Capital, LLC underperformed the S&P 500 by –38.6% annually on this MDGL position. Average cost basis: $279.69. Maximum drawdown during holding period: –24.3%.

πŸ“ˆ Position Alpha vs SPY
-38.6%
annualised excess return

❌ Significantly underperformed the S&P 500 by 38.6% ann.
7 quarters analyzed

πŸ’° Entry Quality
$279.69
+64.0% vs current ($458.66)

Best entry: $279.69 (2018 Q2)  Β·  Worst: $279.69 (2018 Q2)

πŸ›‘οΈ Drawdown Resilience
–24.3%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
67%
buy-side decisions

2 adds Β· 1 trim. Bought during 0 of 3 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
↑ Growing
last 4–5 quarters trend

πŸ“ˆ EcoR1 Capital, LLC has been actively increasing its MDGL allocation β€” a bullish signal from insiders.
Currently 1.65% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    MDGL price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 9 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 75,000 β€” 0% 1.65% $34.4M $458.66
2025 Q2 UNCHANGED 75,000 β€” 0% 1.34% $22.7M $302.64
2025 Q1 UNCHANGED 75,000 β€” 0% 1.47% $24.8M $331.23
2024 Q4 UNCHANGED 75,000 β€” 0% 0.87% $23.1M $308.57
2024 Q3 UNCHANGED 75,000 β€” 0% 0.54% $15.9M $212.22
2024 Q2 UNCHANGED 75,000 β€” 0% 0.64% $21.0M $280.16
2024 Q1 REDUCED 75,000 -124,500 -62.4% 0.51% $20.0M $267.04
2018 Q2 ADDED 199,500 +164,500 +470.0% 5.31% $55.8M $279.69
2017 Q4 INITIATED 35,000 β€” β€” 0.36% $3.2M β€”

🏒 Other funds also holding MDGL

As of 2025 Q4 β€” sorted by position size

PAULSON & CO. INC. 3Y 7Y 30.48% RTW INVESTMENTS, LP 3Y 7Y 11.63% Tao Capital Management LP 3Y 10.53% Avoro Capital Advisors LLC 3Y 7Y 10.35% BAKER BROS. ADVISORS LP 3Y 7Y 7.3% Tri Locum Partners LP 3Y 6.5% MPM BioImpact LLC 3Y 6.45% Nan Fung Group Holdings Ltd 3Y 6.19% Rock Springs Capital Management LP 3Y 7Y 4.17% Resolute Capital Asset Partners LLC 3Y 3.07%
← Back to EcoR1 Capital, LLC Holdings